非酒精性脂肪性肝病患者外周血TH17/Treg细胞的变化及意义

孙亮; 李博; 邱厚匡; 李明友; 林茂锐; 曹东林; 雷达

doi:10.3969/j.issn.1671-038X.2019.11.13

非酒精性脂肪性肝病患者外周血TH17/Treg细胞的变化及意义

- 广东省第二人民医院检验医学部, 广东广州 510310
基金项目:
广东省2015年度自然科学基金——基础与应用基础研究专项资金（No：605）

详细信息

作者简介:
孙亮,男,本科,研究方向:临床医学检验

通讯作者: 孙亮,E-mail:18680496527@163.com

中图分类号: R575

收稿日期: 2019-06-10

Significance of TH17/Treg cells in peripheral blood of patients with nonalcoholic fatty liver disease

- Department of Laboratory Medicine, Guangdong Second People's Hospital, Guangzhou 510310, China

More Information

Corresponding author: SUN Liang, E-mail: 18680496527@163.com

Received Date: 10 June 2019

摘要

摘要: [目的]探辅助性T淋巴细胞17（TH17）/调节性T淋巴细胞（Treg）动态平衡在非酒精性脂肪性肝病（NAFLD）中的作用，为其防治提供新途径和依据。[方法]选择2017年2月~2018年12月我院诊疗的NAFLD患者92例，另取我院体检中心健康体检者40例作为对照。根据CT影像学肝脂肪变分度标准，将NAFLD患者分为轻度、中度和重度肝脂肪变。流式细胞仪检测外周血TH17和Treg细胞比例。ELISA法检测白细胞介素（IL）-17和IL-10因子表达。[结果]NAFLD组TH17细胞比例为（14.26±2.18）%，显著高于对照组的（7.12±1.26）%（P<0.01），NAFLD组Treg细胞比例为（5.13±0.82）%，显著低于对照组的（6.35±1.04）%（P<0.05），NAFLD组TH17/Treg细胞比值为2.78±0.46，显著高于对照组的1.12±0.15（P<0.01）。NAFLD组IL-17因子表达水平为（22.74±4.62）μg/L，显著高于对照组的（12.52±2.13）μg/L（P<0.01），NAFLD组IL-10因子表达水平为（6.18±1.15）μg/L，显著低于对照组的（8.47±1.54）μg/L（P<0.05），NAFLD组IL-17/IL-10比值为3.68±0.60，显著高于对照组的1.48±0.25（P<0.01）。轻度、中度和重度肝脂肪变NAFLD患者间TH17、Treg细胞比例、TH17/Treg比值、IL-17、IL-10因子表达以及IL-17/IL-10比值间存在显著差异（P<0.05）。[结论]NAFLD患者存在Th17/Treg失衡，其失衡与患者肝脂肪病变的程度密切相关，调整Th17/Treg失衡有望成为NAFLD防治的新思路。
- 非酒精性脂肪性肝病 /
- 辅助性T淋巴细胞17 /
- 调节性T淋巴细胞
Abstract: [Objective] To detect the role of TH17/Treg dynamic balance in nonalcoholic fatty liver disease(NAFLD).[Methods] 92 NAFLD patients were enrolled in this study.Another 40 healthy individuals in the physical examination center of our hospital were taken as control.NAFLD patients were divided into mild, moderate and severe hepatic steatosis according to CT imaging criteria for liver steatosis grading.The ratios of TH17 and Treg cells in peripheral blood were measured by flow cytometry.IL-17 and IL-10 expression was detected by ELISA.[Results] The percentage of TH17 cells in NAFLD group was (14.26±2.18)%, which was significantly higher than that of (7.12±1.26)% in control group(P<0.01).Treg cells in NAFLD group was (5.13±0.82)%, which was significantly lower than that of (6.35±1.04)% in control group(P<0.05).The ratio of TH17/Treg in NAFLD group was 2.78±0.46, which was significantly higher than that of 1.12±0.15 in control group(P<0.01).The expression of IL-17 in NAFLD group was (22.74±4.62) μg/L, which was significantly higher than that of (12.52±2.13) μg/L in control group(P<0.01).IL-10 in NAFLD group was (6.18±1.15) μg/L, which was significantly lower than that of (8.47±1.54) μg/L in control group(P<0.05).The ratio of IL-17/IL-10 in NAFLD group was 3.68±0.60, which was significantly higher than that of 1.48±0.25 in control group(P<0.01).There were significant differences in TH17, Treg cell, TH17/Treg, IL-17 expression, IL-10 expression and IL-17/IL-10 among patients with NAFLD with mild, moderate and severe hepatic steatosis(P<0.05).[Conclusion] There is Th17/Treg imbalance in NAFLD patients, which is closely related to the degree of hepatic steatosis.Adjusting Th17/Treg imbalance might be expected to become a new way to prevent and treat NAFLD.
- non-alcoholic fatty liver diseas /
- Th17 /
- Treg

HTML全文

参考文献(12)

[1]	Chalasani N, Younossi Z, Lavine JE, et al..The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases[J].Hepatology, 2017, 67(1):328-357.
[2]	Haas JT, Francque S, Staels B.Pathophysiology and mechanisms of nonalcoholic fatty liver disease[J].Annu Rev Physiol, 2016, 78(1):181-205.
[3]	曲宝戈.脂肪性肝病患者炎症、免疫改变及治疗的研究现状及瞻望[J].世界华人消化杂志, 2016, 24(19):2931-2942.
[4]	Swiderska M, Jaroszewicz J, Stawicka A, et al.The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease[J].Clin Exp Hepatol, 2017, 3(3):127-134.
[5]	中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].传染病信息, 2018, 31(5):393-402, 420.
[6]	李静, 唐洁婷, 茅益民.非酒精性脂肪性肝病和非酒精性脂肪性肝炎治疗的现状与未来[J].肝脏, 2018, 23(9):756-759.
[7]	李军祥, 陈誩, 王允亮.非酒精性脂肪性肝病中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志, 2017, 25(11):805-811.
[8]	王彦丽, 郝礼森, 张铁强, 等.非酒精性脂肪性肝病患者外周血T细胞亚群的变化及意义[J].实用预防医学, 2018, 25(12):1473-1475.
[9]	高伟华, 葛宽雪, 向晓星.辅助性T淋巴细胞17和调节性T淋巴细胞及其平衡改变与非酒精性脂肪性肝病的关系[J].临床肝胆病杂志, 2018, 34(6):1347-1350.
[10]	唐涛, 蔡旭华, 李伟平, 等.HIF-1α、Treg和Th17在非酒精性脂肪性肝病患者外周血中的表达及其临床意义[J].中华全科医学, 2017, 15(10):1672-1674, 1820.
[11]	杨毅, 张晓玲, 官俏兵, 等.樟芝多糖通过CD4⁺CD25⁺Foxp3⁺调节性T细胞对小鼠非酒精性脂肪性肝病的保护作用[J].中国现代应用药学, 2018, 35(3):382-387.
[12]	Su L, Wu Z, Chi Y, et al.Mesenteric lymph node CD4⁺T lymphocytes migrate to liver and contribute to non-alcoholic fatty liver disease[J].Cell Immunol, 2019, 337(1):33-41.